.rll-youtube-player .play{--wpr-bg-c37c146f-68d7-4eee-92eb-4b9d66b82b18: url('https://newsimc.com/wp-content/plugins/wp-rocket/assets/img/youtube.png');}.perfmatters-lazy-youtube .play{--wpr-bg-efe599f9-0f5b-46ef-a066-4378b3b2b242: url('https://newsimc.com/wp-content/plugins/perfmatters/img/youtube.svg');}

Atreca Inc. (BCEL) Stock Exhibits Minor Volatility Ahead of Upcoming SITC Presentations

Atreca Inc. (BCEL) stock prices were down by 1.77% as of the market closing on October 1st, 2021. This brought the price per share down to USD$6.12 at the end of the trading day.

BCEL Stock to Present at SITC

October 1^st, 2021 saw BCEL stock announce that it would be undertaking two poster presentations at the SITC 2021 Annual Meeting. The clinical-stage biotechnology company is allocating resources towards being prepared to present in Washington, D.C from November 10^th to November 14th, 2021. The first poster will be titled “First-in-Human Results with the Novel Tumor-Targeting Antibody ATRC-101: Phase 1b Study in Patients with Solid Tumors”. The second presentation will be titled “Preclinical Evaluation of Pegylated Liposomal Duxorubicin or Doxorubicin with mATRC-101 in the EMT6 Syngeneic Mouse Model”.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

ARTC-101 Initial Data

BCEL stock recently announced initial summary data from the dose escalation portion of its Phase 1b trial of ATRC-101 in multiple solid tumors. The treatment was well-tolerated with no dose-limited toxicities having been reported. Either of the total of 20 participannts evaluable prior to the data cut-off in the analysis reported experiencing stable disease. SD was their best RECIST response, with four participants having reported a reduction in tumor size. The disease control observed in the study was associated with ATRC-101 target expression. Preliminary biomarker analysis was in line with the proposed mechanism of action for ATRC-101. The peak concentration of ARTC-101 was dose proportional and minimal accumulation was observed following the administering of multiple doses.

Promising Financials

The company reported a solid liquidity position at the end of the prior quarter. BCEL stock had USD$182.3 million in cash and cash equivalents, and short term investments, as of June 30^th, 2021. Research and development costs for the quarter came out to USD$19 million. This included non cash, share based compensation costs of USD$1.9 million. G&A costs for the quarter were reported in the amount of USD$8 million. Net loss for the quarter came out to USD$26.7 million, representing a net loss per basic and diluted share attributable to common stockholders in the amount of USD$0.72.

Future Outlook for BCEL Stock

The company reported a promising quarter, as evidenced by the strength of its financial reports for the most recent quarter. BCEL stock is poised to capitalize on the expanded exposure it will garner during its upcoming presentations. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate consistent and organic growth in shareholder value over the long term.